A Phase <scp>II</scp> Pilot Study of Anti‐ <scp>PD</scp> ‐ <scp>L1</scp> , Durvalumab, and a <scp>PARP</scp> Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation

Authors

Seth M. Steinberg (ORCID: https://orcid.org/0000-0002-8280-551X)
Jayakumar R. Nair (ORCID: https://orcid.org/0000-0002-4478-4607)
Ashley Cimino‐Mathews (ORCID: https://orcid.org/0000-0002-0638-7969)
B. Brooke Solarz
Bernadette Redd (ORCID: https://orcid.org/0000-0001-9058-9485)
Min-Jung Lee (ORCID: https://orcid.org/0000-0003-3943-8133)
Stanley Lipkowitz (ORCID: https://orcid.org/0000-0002-6103-2255)
Jung‐Min Lee (ORCID: https://orcid.org/0000-0003-1280-5909)
N Sato (ORCID: https://orcid.org/0009-0007-1772-3183)
Ann McCoy (ORCID: https://orcid.org/0000-0002-0990-3252)
Alexandra S. Zimmer (ORCID: https://orcid.org/0000-0001-6789-0982)
Shraddha Rastogi (ORCID: https://orcid.org/0000-0003-0680-0407)
Elliot Levy
Takeo Fujii (ORCID: https://orcid.org/0000-0003-3747-2688)

Institutions

National Institutes of Health (US)
Johns Hopkins University (US)
Johns Hopkins Medicine (US)
National Cancer Institute (US)
Center for Cancer Research (US)
National Institutes of Health Clinical Center (US)

Publication Details

Journal: Cancer Medicine
Published: 2025-12-01
DOI: https://doi.org/10.1002/cam4.71220
Primary Topic: PARP inhibition in cancer therapy
Type: article
Field-Weighted Citation Impact: 0.00

Funders

U.S. Department of Health and Human Services
AstraZeneca
National Institutes of Health
National Cancer Institute

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

A Phase II Pilot Study of Anti‐ PD ‐ L1 , Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation

Seth M. Steinberg, Jayakumar R. Nair, Ashley Cimino‐Mathews, B. Brooke Solarz et al.

Dec 1, 2025

Cancer Medicine

PARP inhibition in cancer therapy

article

A Phase II Pilot Study of Anti‐ PD ‐ L1 , Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation

Seth M. Steinberg, Jayakumar R. Nair, Ashley Cimino‐Mathews, B. Brooke Solarz, Bernadette Redd, Min-Jung Lee, Stanley Lipkowitz, Jung‐Min Lee, N Sato, Ann McCoy, Alexandra S. Zimmer, Shraddha Rastogi, Elliot Levy, Takeo Fujii

December 1, 2025article en

Abstract

No abstract available for this paper.

Cancer MedicineVol. 14(23)

National Institutes of Health (US), Johns Hopkins University (US), Johns Hopkins Medicine (US), National Cancer Institute (US), Center for Cancer Research (US), National Institutes of Health Clinical Center (US)

U.S. Department of Health and Human Services, AstraZeneca, National Institutes of Health, National Cancer Institute

Openalex Percentile: Top 45%

PARP inhibition in cancer therapy

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A Phase <scp>II</scp> Pilot Study of Anti‐ <scp>PD</scp> ‐ <scp>L1</scp> , Durvalumab, and a <scp>PARP</scp> Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation — Seth M. Steinberg, Jayakumar R. Nair, et al. · Cancer Medicine (2025) | TGRS Research Map | TGRS